Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Target Therapeutics (US) gets 510(k) for intracranial coil:

This article was originally published in Clinica

Executive Summary

Target Therapeutics (US) has received FDA clearance to market the Guglielmi detachable coil for intracranial aneurysms. The soft platinum alloy microcoil is intended for use in inoperable or surgical high-risk stroke patients. The coil is delivered using Target's Tracker microcatheter and released electrically. Nearly 40,000 intracranial aneurysms are diagnosed in the US every year and about 25% of these are deemed either inoperable or high-risk for surgical repair.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT093295

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel